PDAC - PANCREATIC DUCTAL ADENOCARCINOMA
Clinical trials for PDAC - PANCREATIC DUCTAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new PDAC - PANCREATIC DUCTAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for PDAC - PANCREATIC DUCTAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for hard-to-treat cancers: targeted combo trial opens
Disease control Recruiting nowThis study tests a new oral drug, TNG462, combined with other treatments for people with pancreatic or non-small cell lung cancer that has lost the MTAP gene and, in some cases, has a RAS mutation. The trial has two phases: first to find the safest dose, then to see how well the …
Matched conditions: PDAC - PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Tango Therapeutics, Inc. • Aim: Disease control
Last updated Jun 17, 2026 12:10 UTC
-
New hope for pancreatic cancer: targeted drug combo enters phase 3 trial
Disease control Recruiting nowThis study tests a new drug called daraxonrasib, which targets a specific protein (RAS) that helps cancer grow. It is given alone or with standard chemotherapy to people with metastatic pancreatic cancer that has spread. The goal is to see if it helps patients live longer or slow…
Matched conditions: PDAC - PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jun 17, 2026 12:08 UTC
-
Last-Resort drug access opens for advanced pancreatic cancer patients
Disease control AVAILABLEThis program offers daraxonrasib to adults with metastatic pancreatic cancer that has worsened after prior treatment and who have no other good options. It is for patients who cannot join ongoing clinical trials. The goal is to provide access to this experimental drug when no sta…
Matched conditions: PDAC - PANCREATIC DUCTAL ADENOCARCINOMA
Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
New pill aims to keep pancreatic cancer away after surgery
Disease control Recruiting nowThis study tests a new drug called daraxonrasib in people with pancreatic cancer who have already had surgery and chemotherapy. The goal is to see if taking the drug can delay or prevent the cancer from returning compared to just watching and waiting. About 500 adults will be ran…
Matched conditions: PDAC - PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jun 15, 2026 19:06 UTC
-
Blood sugar monitoring may boost pancreatic cancer treatment
Disease control Recruiting nowThis study looks at whether closely tracking and managing blood sugar levels can help people with pancreatic cancer. About 50 participants will wear a continuous glucose monitor while receiving standard chemotherapy. They will be split into two groups: one with tight blood sugar …
Matched conditions: PDAC - PANCREATIC DUCTAL ADENOCARCINOMA
Phase: NA • Sponsor: British Columbia Cancer Agency • Aim: Disease control
Last updated Jun 15, 2026 19:04 UTC
-
New hope for Hard-to-Treat cancers: targeted drug enters human trials
Disease control Recruiting nowThis early-phase study tests a new drug called ALTA3263 in adults with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have a specific genetic change called a KRAS mutation. The main goal is to check the drug's safety and find the right dose. About 448 pa…
Matched conditions: PDAC - PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Alterome Therapeutics, Inc. • Aim: Disease control
Last updated Jun 15, 2026 18:57 UTC
-
Nanocell attack: new combo therapy takes on tough pancreatic cancer
Disease control Recruiting nowThis study tests whether adding specially designed nanocells (tiny particles that deliver a potent drug directly to cancer cells) to standard chemotherapy can help people with metastatic pancreatic cancer live longer. About 144 adults whose cancer has worsened despite prior treat…
Matched conditions: PDAC - PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Engeneic Pty Limited • Aim: Disease control
Last updated Jun 12, 2026 12:07 UTC
-
New drug targets tumors from inside: early trial begins
Disease control Recruiting nowThis early-phase trial tests a new drug called AVA6103 in about 174 adults with advanced solid tumors (like pancreatic, lung, or breast cancer) that have not responded to standard treatments. The drug is designed to activate only inside tumors, aiming to kill cancer cells while l…
Matched conditions: PDAC - PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Avacta Life Sciences Ltd • Aim: Disease control
Last updated Jun 10, 2026 13:24 UTC
-
New combo therapy aims to slash deadly leaks after pancreatic cancer surgery
Disease control Recruiting nowThis trial tests whether giving three treatments together—two medicines and a surgical patch—can lower the risk of major complications after Whipple surgery for pancreatic cancer and other tumors. The study includes 400 high-risk patients with a small pancreatic duct. If successf…
Matched conditions: PDAC - PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE4 • Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Disease control
Last updated Jun 10, 2026 13:24 UTC
-
New pill targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called BBO-11818 in people with advanced cancers that have a KRAS mutation, including lung, pancreatic, and colorectal cancers. The main goals are to check safety and find the best dose, while also seeing if the drug can shrink tumors. Abou…
Matched conditions: PDAC - PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated Jun 08, 2026 13:11 UTC
-
New hope for pancreatic cancer: drug combo enters phase 3 trial
Disease control Recruiting nowThis study tests whether adding the experimental drug atebimetinib to standard chemotherapy helps people with metastatic pancreatic cancer live longer. About 510 adults who have not had prior treatment will receive either the new combination or standard chemo alone. The goal is t…
Matched conditions: PDAC - PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Immuneering Corporation • Aim: Disease control
Last updated Jun 08, 2026 13:06 UTC
-
New hope for hard-to-treat pancreatic cancer: targeted drug combo enters phase 3 trial
Disease control Recruiting nowThis study tests whether adding an experimental drug called zoldonrasib to standard chemotherapy helps people with a specific genetic form of metastatic pancreatic cancer (KRAS G12D mutation) live longer without their cancer growing. About 670 adults with advanced pancreatic canc…
Matched conditions: PDAC - PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jun 08, 2026 13:04 UTC
-
New hope for Hard-to-Treat cancers: experimental drug enters human trials
Disease control Recruiting nowThis early-stage study tests an experimental drug called TJ033721 (givastomig) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how the body processe…
Matched conditions: PDAC - PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: I-Mab Biopharma US Limited • Aim: Disease control
Last updated Jun 03, 2026 12:07 UTC
-
Simple breath test could spot pancreatic cancer sooner
Diagnosis Recruiting nowThis study is testing a non-invasive breath test to detect pancreatic cancer earlier. Researchers will collect breath samples from over 6,000 people referred for possible pancreatic cancer. The test looks for tiny molecules made by cancer cells. If accurate, it could help doctors…
Matched conditions: PDAC - PANCREATIC DUCTAL ADENOCARCINOMA
Sponsor: Imperial College London • Aim: Diagnosis
Last updated Jun 22, 2026 12:01 UTC
-
Blood test hunt for silent killer: 5,000 High-Risk volunteers sought
Diagnosis Recruiting nowThis study aims to see if adding simple blood tests and symptom reviews to standard screening can catch pancreatic cancer earlier in people with a high genetic risk. Researchers will enroll 5,000 participants who have certain gene mutations linked to pancreatic cancer. The goal i…
Matched conditions: PDAC - PANCREATIC DUCTAL ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Diagnosis
Last updated Jun 18, 2026 11:49 UTC
-
Simple breath test could spot pancreatic cancer sooner
Diagnosis Recruiting nowThis study aims to develop a non-invasive breath test to detect pancreatic cancer earlier. Pancreatic cancer is often diagnosed late because early symptoms are vague. The test measures tiny molecules in breath that may signal cancer. Researchers will collect breath and urine samp…
Matched conditions: PDAC - PANCREATIC DUCTAL ADENOCARCINOMA
Sponsor: Imperial College London • Aim: Diagnosis
Last updated Jun 17, 2026 12:08 UTC
-
New app aims to ease pancreatic cancer treatment journey
Symptom relief Recruiting nowThis study is testing a smartphone app called PDAC-PATHWAYS designed to provide information and support to people with pancreatic cancer who are about to start neoadjuvant therapy (treatment before surgery). The app includes educational modules and tools to help patients cope. Re…
Matched conditions: PDAC - PANCREATIC DUCTAL ADENOCARCINOMA
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 23, 2026 11:58 UTC
-
Lab-Grown mini tumors could unlock personalized pancreatic cancer care
Knowledge-focused Recruiting nowThis study aims to grow miniature versions of pancreatic tumors (called organoids) from small biopsy samples taken during a routine endoscopic procedure. Researchers will check if these lab-grown organoids match the original tumor's genetics and behavior. The goal is to eventuall…
Matched conditions: PDAC - PANCREATIC DUCTAL ADENOCARCINOMA
Phase: NA • Sponsor: IHU Strasbourg • Aim: Knowledge-focused
Last updated Jun 12, 2026 12:04 UTC
-
5,000 volunteers needed to help detect pancreatic cancer sooner
Knowledge-focused Recruiting nowThis study enrolls 5,000 people at high risk for pancreatic cancer to donate blood, pancreatic juice, and medical images over 10 years. Researchers will use this information to develop and validate tests that can detect pancreatic cancer earlier, when it may be more treatable. Pa…
Matched conditions: PDAC - PANCREATIC DUCTAL ADENOCARCINOMA
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 01, 2026 18:06 UTC